ReviewEMBO molecular medicine2025
Pertussis before, during and after Covid-19.
Review in EMBO molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Global, regional and national burden of pertussis in 1990-2023: a Global Burden of Disease study.Nature medicine · 2026Article
- History of whooping cough in Colombia: Endemic infant deaths, outbreaks and epidemicsBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Development of High-Throughput Serum Bactericidal Assays forVaccines · 2026Article
- Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study.Pediatric pulmonology · 2026Article
- Diagnostic Performance and Clinical Outcomes of Pertussis in Hospitalized Children in Relation to Available Vaccination Status: A Retrospective Cohort Study.Infectious diseases and therapy · 2026Article
- Pertussis resurgence after the COVID-19 pandemic in four Western Pacific Countries and the USA, highlighting the 2025 outbreak in Japan.Scientific reports · 2026Article
- Unadjuvanted antenatal pertussis OMV vaccination drives enhanced and durable humoral immunity in offspring.Frontiers in immunology · 2026Article
- Trends and disparities in the research and development of infectious disease vaccines from 2015 to 2025.Human vaccines & immunotherapeutics · 2025Article
- Global burden, inequalities, frontier dynamics, and risk factors of sudden infant death syndrome, 1990-2021: a systematic analysis from the global burden of disease study 2021.Translational pediatrics · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After the Covid-19 pandemic, pertussis has made a spectacular comeback in Europe and many other parts of the world, while during the pandemic it had essentially disappeared because of the social distancing requirements. However, even before the Covid-19 pandemic, the disease was on the rise in many countries, especially those that have replaced whole-cell pertussis vaccines by acellular pertussis vaccines. Several reasons may account for this upsurge, including strain adaptation to escape vaccine-induced immunity, rapid waning of immunity after vaccination and the failure of current vaccines to prevent infection by and transmission of the causative agent Bordetella pertussis. Various strategies have been deployed to control the disease, the most effective of which is maternal vaccination during pregnancy to protect the newborn against the most severe and deadly forms of the disease. However, ultimate control of pertussis likely requires novel vaccines, which prevent infection and transmission, not only disease. One of them is the live attenuated BPZE1 vaccine, which has shown promise in pre-clinical and clinical studies and may therefore perhaps become a gamechanger.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.